REG - Feedback PLC - NHS Progress and Business Update

FeedbackAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260420:nRST0920Ba&default-theme=true

RNS Number : 0920B  Feedback PLC  20 April 2026

Feedback plc

 

NHS Progress and Business Update

 

Significant scale opportunities as positive discussions continue and further
funding awarded

 

Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the clinical
infrastructure specialist, announces an update on the Company's continued
dialogue with NHS stakeholders with a view to fulfilling productivity
requirements across the NHS.

 

Previous indications were that a central NHS decision would be made in
relation to a potential contract for adoption of a widescale programme for
Bleepa around the end of the 2025/26 NHS financial year (31 March 2026). The
Company now understands that decisions will be delayed by at least 6-9 months
due to NHS internal factors. Nevertheless, discussions have continued to
progress positively with central NHS stakeholders regarding at scale
opportunities for Bleepa which the Board believes have the potential to be
aligned to new frontline digitisation funding which is expected to become
available in the 2026/27 NHS financial year.

 

Despite the delayed decision, NHSE has extended Bleepa's existing licences at
Queen Victoria Hospital NHS Foundation Trust ("QVH") (annualised contract
value £495k) to cover the 9-month period ending in December 2026. This
ensures that the Bleepa pathway programme can continue to expand within Sussex
whilst discussions continue around the potential for a larger scale rollout.
Bleepa's usage at QVH continues to grow in both user numbers and use cases.
The Company recently partnered with Patients Know Best to deliver a pioneering
new insomnia pathway in Sussex, and we are in active discussions with QVH
around additional use cases, product optimisation and additional funding in
this calendar year.

 

Focus on Core Growth Opportunities

Following discussion with the Royal Berkshire NHS Foundation Trust, the
Company will not be renewing its contract for photocapture with the Trust
which came to the end of its 3-year term at the end of March 2026. This is
part of a managed process to focus on utilising internal resources to optimise
Bleepa for core pathway opportunities which the Company believes have the
potential to deliver significantly larger revenues.

 

The Bleepa pathway use case is also being demonstrated for internal pathways
at the Northern Care Alliance NHS Foundation Trust where the Company has
agreed a further annual contract extension with the Trust, providing the
opportunity to further build the business case for expansion and funding
opportunities.

 

The Board remains confident that the Company continues to provide a unique
value proposition that could deliver significant impact against the NHS'
primary objective of waitlist reduction and elective recovery. The Company
remains in active dialogue with national NHS stakeholders underpinning
confidence in the mid-term opportunity for Bleepa. The Company's cash position
is being carefully managed and, based on current plans, provides a runway
extending to mid-2027.

 

Dr Tom Oakley, CEO of Feedback, said:

 

"Despite the delay in the NHS's decision, we remain optimistic of a positive
outcome. The additional funding to extend Bleepa licences at QVH demonstrates
an ongoing commitment to our solutions.

 

"Whilst we await the outcomes of central NHS decisions, we will focus on
expanding the programme at QVH and other pathway opportunities, whilst
selectively exploring alternative opportunities to create shareholder value."

 

 

Enquiries:

 

 Feedback plc                                +44 (0) 20 3997 7634

 Tom Oakley, CEO                             IR@fbk.com (mailto:IR@fbk.com)

 Emma Oswick, CFO

 Panmure Liberum Limited (NOMAD and Broker)  +44 (0)20 7886 2500

 Emma Earl/Mark Rogers (Corporate Finance)

 Rupert Dearden (Corporate Broking)

 Walbrook PR Ltd;                            Tel: 020 7933 8780 or feedbackplc@walbrookpr.com
                                             (mailto:feedbackplc@walbrookpr.com)
 Nick Rome/Marcus Ulker                      07748 325 236 or 07867 984 082

 

 

About Feedback plc

 

Feedback plc is the strategic partner to unlock productivity in health and
care through digital connectivity and asynchronous collaboration. With proven
expertise in system integration, we enable teams to work flexibly, share
information securely, and deliver care more efficiently.

 

Bleepa® is an award-winning collaboration platform that improves the quality
and productivity of patient pathways enabling health and care organisations to
hit targets with their existing clinical workforce. We achieve this by
connecting digital infrastructure across systems, enabling asynchronous
working, reducing geographic barriers and removing unnecessary appointments.

 

Bleepa supports the shift from analogue to digital and from hospital to
community-based care, by uniting essential data and teams to enhance clinical
decision making and enable better coordinated care.

 

The Company has a number of growth opportunities domestically and
internationally across a range of public and private healthcare markets
including the NHS. Our highly scalable software-as-a-service (SaaS) based
model is expected to provide increasing levels of revenue visibility as the
Company grows its customer base.

 

https://fbk.com (https://fbk.com)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDBKLLFQZLZBBL



            Copyright 2019 Regulatory News Service, all rights reserved